Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO—A—B-D-E-(G)s-K wherein R1, R2, X, A, B, D, E, G, K and s have the meanings stated in the description. The compounds have antineoplastic activity.

Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L ??(I), and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L,??(I) and acid salts thereof, wherein A, B, D, E, F, G and K are ?-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a ?-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Abstract: Techniques for remotely building and managing software applications are provided. Computer code of the principal developer (e.g., source code, object code or libraries) that is not to be shared with external parties is stored on a restricted internal server while computer code of a third party supplier or customer is stored on a shared server by the supplier. A daemon executes on the restricted server to access the computer code on the shared server, download the computer code to the restricted server and call the internal compiler, linker, etc. to build the complete software application. The build is then stored or uploaded on the shared server (by the daemon) for the supplier or customer to access. Files related to the build that are desirable not to share (e.g., map files and all sensitive source code files) can be stored on the restricted server.

Abstract: The present invention provides antineoplastic peptides of formula I, R1R2N—CHX—CO-A-B-D-E-(G)s-K ??I wherein R1, R2, X, A, B, D, E, G, K, and s have the meanings stated in the description. The compounds have antineoplastic activity.

Abstract: The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1? converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure: and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,

Abstract: Novel arylsulfonamide ether compounds and pharmaceutical compositions thereof are described. The use of the novel arylsulfonamide ether compounds and pharmaceutical compositions thereof as inhibitors of interleukin-1&bgr; converting enzyme and other cysteine proteases in the ICE family is also decribed. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis using a compound of the invention or a pharmaceutical composition thereof are described.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G)r-(K)s-L  (I), and acid salts thereof, wherein A, B, D, E, F, G and K are &agr;-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a &bgr;-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Abstract: The present invention provides compounds of the formula where R1-R5 are each, independently, a hydrogen atom or a normal or branched C1-C6-alkyl group; A is a methionyl, phenylalanyl or phenylglycyl residue; n is 0 or 1; R6 is a hydrogen atom; and R7 is a carbocylic group, an aromatic group, a C1-C4-alkyl group, a pyridylalkyl group or a heterocyclic group. In another embodiment, R6 is benzyl or —C(O)OR8, where R8 is a C1-C6-alkyl group, and R7 is a heteroaromatic group, such as a 2-thiazolyl group.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I

Abstract: The present invention provides antineoplastic peptides of formula I,

Abstract: Compounds of the formula where R1, R2, R3 and R4 have the meaning stated in the description, and a process for preparing them are described. The compounds are suitable as starting material for synthesizing substances which are active against tumors.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula I,A-B-D-E-F-(G).sub.r -(K).sub.s -L (I),and acid salts thereof, wherein A, B, D, E, F, G and K are .alpha.-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a .beta.-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Abstract: Compounds of the present invention include cell growth inhibitors which are peptides of Formula IA--B--D--E--F--G (I)and acid salts thereof, wherein A, D, and E are .alpha.-amino acid residues, B is an .alpha.-amino acid residue or an .alpha.-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a .beta.-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.

Abstract: A process for preparing pentapeptides of the formula I ##STR1## where A and R.sup.1 -R.sup.3 have the stated meanings, comprises assembling the pentapeptide stepwise starting from a prolinamide of the formula II ##STR2## where R.sup.1 and R.sup.2 have the abovementioned meanings, and eliminating the group --NR.sup.1 R.sup.2 by hydrolysis where appropriate the peptide obtained in this way.

Abstract: The present invention relates to novel peptides useful as anti-cancer agents. The compounds of the invention are of Formula I,A-B-D-E-F-G (I)A, B, D, and E are .alpha.-amino acid residues. In one embodiment, F is an azacycloalkanecarboxylic acid residue. In this embodiment, G is a monovalent radical, for example, a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group. In another embodiment, F is an azacycloalkyl group and G is a heteroaryl group connected to F by a carbon-carbon bond.In another embodiment, the invention includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

Abstract: The present invention provides anti-tumor peptides of Formula I,A--B--NR.sup.3 --CHD--CH(OCH.sub.3)--CH.sub.2 CO--E--K (I),and the acid salts thereof. A is an amino acid residue selected from the group consisting of N-methyl-D-prolyl, N-methyl-D-homoprolyl and N,N-dimethyl-2-ethylphenylglycyl, or an amino acid residue of the formula R.sup.1 R.sup.2 N--CHX--CO, wherein R.sup.1 is a-methyl group or an ethyl group, R.sup.2 is a hydrogen atom, a methyl group or an ethyl group, and X is an alkyl group. B is an amino acid residue selected from the group consisting of valyl, isoleucyl, leucyl, and 2-t-butylglycyl. R.sup.3 is a hydrogen atom or a methyl group. D is a normal or branched C.sub.2 -C.sub.5 -alkyl group. E is an amino acid residue selected from the group consisting of prolyl, homoprolyl, 5-methylprolyl, and phenylalanyl, or E is a residue derived from an amino acid comprising a pyrrolidine group. K is an alkoxy group or an amino group.

Abstract: Compounds of the formula ##STR1## where R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meaning stated in the description, and a process for preparing them are described. The compounds are suitable as starting material for synthesizing substances which are active against tumors.